[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neisseria-meningitidis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neisseria-meningitidis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100644627","metagenomic-analysis-of-the-pharynx-in-high-risk-partners-100644627",false,"NCT07671014","Metagenomic Analysis of the Pharynx in High Risk Partners","A Preliminary Investigation to Determine the Utility of Using Metagenomic Analysis of Pharyngeal Samples Taken From Partners of Patients Diagnosed With Gonorrhoea to Identify Organisms, Antibiotics Resistance and Virulence Factors of Neisseria Species and the Impact of STI Prevention Strategies (4CMenB Vaccination and DoxyPEP)","Inclusion Criteria:\n\n* Partner alerted of their risk about being a partner of someone diagnosed with Neisseria Gonorrhea using the digital partner notification software SXT and then booking an appointment for standard of care testing.\n\nExclusion Criteria:\n\n* Under 18 years, unable to speak English","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The Neisseria gonorrhoea (NG) epidemic in England is at the highest level in one hundred years of public health records. The World Health Organisation has listed NG as one of the top five bacterial infections globally because of the ability of the bacteria to develop resistance to antibiotics. Neisseria meningitidis (NM) is a common pharyngeal commensal and it has been shown to be in one in five men who have sex with men (MSM) in London.\n\nIn the last year sexual health clinics have had a growing number of MSM presenting with urethritis \u002F proctitis that were treated for NG on the day only to be found later to have been infected with NM from the culture. It appear that virulence factors have been passed from NG to NM enabling these bacteria to infect the urogenital and anal mucosa; consequently, NM in some cases is a new Sexually Transmitted Infection (STI). In 2025, two STI prevention interventions were rolled out in an attempt to address the gonorrhoea \\& syphilis epidemics and these were the 4CMenB vaccine and doxycycline post exposure prophylaxis (DoxyPEP).\n\nThis study will recruit sexual partners of patients who have been diagnosed with NG and the investigators will ask the participant for one additional pharyngeal sample for research that will not impact on their standard of care. The additional sample will be tested using metagenomics, that is where all non-human DNA is analysed, and the initial focus will be on NG or NM infection, co-infection, genes for virulence and antibiotic resistance from whole genome sequencing.\n\nThe metagenomic analysis is being undertaken for research purpose only; however, secondary outcomes will look for other STIs in the pharyngeal sample and sample turn around time to inform the management of patients. Any additional STI identified will have validated testing to confirm diagnosis.",[24,25,26,27],"Gonorrhea","Neisseria Gonorrhea","Neisseria Meningitidis","Metagenomic Next Generation Sequencing",[24,29,30,31],"Metagenomic testing","Neisseria Gonorrhoea","Neisseria Meningitis","NOT_YET_RECRUITING","2026-06-26",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":20},"2026-07-14",{"date":40,"type":20},"2027-02-28",{"name":42,"class":43},"Guy's and St Thomas' NHS Foundation Trust","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":5},"100608146","phase-4-menb-fhbp-or-menacwy-ttmenb-fhbp-vaccine-in-menb-4c-primed-young-adults-100608146","NCT07197762","MenB-FHbp or MenACWY-TT\u002FMenB-FHbp Vaccine in MenB-4C Primed Young Adults","Immunogenicity of a Single Dose of MenB-FHbp or MenACWY-TT\u002FMenB-FHbp in MenB-4C Primed Young Adults","Inclusion Criteria:\n\n* Provides written informed consent before any study procedures are performed.\n* Be able to understand and agree to comply with planned study procedures and be available for all study visits.\n* Subject is in good health as determined by vital signs, medical history, targeted physical examination (if indicated), and the judgment of the investigator.\n* Vaccinated with 2-dose Bexsero primary series at least 2.5 years before vaccination. Must confirm vaccination status and dates of administration through GRITS, healthcare provider, or other official documentation\n* Women of childbearing potential must agree to use or have practiced true abstinence2 or use at least one acceptable primary form of contraception from 28 days prior through 28 days after vaccination.\n* Women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours before vaccination\n\nExclusion Criteria:\n\n* Subject has an acute illness with fever (temperature ≥100.4 °F) within 72 hours before vaccine administration.\n* Subject is currently pregnant or breastfeeding an infant\u002Fchild.\n* Has any medical disease or condition that, in the opinion of the site PI or appropriate sub-investigator, precludes study participation. (Including acute, subacute, intermittent,t or chronic medical disease or condition that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subject's successful completion of this trial. Chronic medical conditions that are stable, with no escalation in medication doses or new medications administered in the preceding 3 months, will not be considered exclusionary.)\n* Presence of self-reported or medically documented significant medical or psychiatric condition(s) as determined by the investigator.\n* Received or plans to receive a licensed, live vaccine within 4 weeks before or after the study vaccination.\n* Received or plans to receive a licensed, inactivated vaccine within 2 weeks before through 4 weeks after the study vaccination.\n* Any previous severe hypersensitivity or anaphylactic reaction to any vaccine or vaccine-related component\n* Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.\n* Received any MenB vaccine within the last 2.5 years before vaccination.\n* Received more than 2 doses of Bexsero or any other MenB vaccine(s) (e.g. Trumenba or Penbraya)\n* Any known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as participants with congenital or acquired defects in B-cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy \\>20 mg per day for ≥14 days, or those receiving immunosuppressive therapy. Participants with terminal complement deficiency are excluded from participation in this study.\n* Significant neurological disorder or history of seizure (excluding simple febrile seizure).\n* Any neuroinflammatory condition or autoimmune condition requiring immunomodulatory treatment, including, but not limited to, Guillain-Barré syndrome, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.",true,"25 Years",{"count":54,"type":20},125,"INTERVENTIONAL",[57],"PHASE4","The goal of this clinical trial is to determine the immunogenicity of certain vaccines in protecting against meningitis B (MenB) in young adults who have previously received a different MenB vaccine.\n\nThe main questions it aims to answer are:\n\n* How many participants are protected against four key types of MenB bacteria before and after getting the new vaccine?\n* How strong is the immune response after vaccination, and how many people show a noticeable boost in immune response?",[26],[61,62,63,64],"MenACWY-TT\u002FMenB-FHbp [Penbraya, Pfizer]","Meningococcus B","MenB-FHbp [Trumenba, Pfizer]","Neisseria meningitidis serogroup B","RECRUITING","2025-12-19",{"date":68,"type":36},"2025-12-22",{"date":70,"type":36},"2025-11-04",{"date":72,"type":20},"2026-12",{"name":74,"class":43},"Emory University"]